|
|
|
|
|
|
TiGenix NV is the European leader in research and development for cell therapy products used to treat damaged and arthritic joints.
At the end of 2012, the group had a portfolio of 3 products in clinical development including 1 in phase III (Cx601 for the Crohn's disease treatment), 1 in phase II (Cx611 for the rheumatoid arthritis), 1 in phase I (Cx621 for the autoimmune diseases treatment) and 2 products in preclinical study phase.
|
|
| Surperformance© rating of Tigenix NV | |
|
|
Overall rating |
In sector |
In country |
| Trading Rating |
|
|
|
| Investor Rating |
|
|
|
| Growth (Revenue) |
|
|
|
| Valuation |
|
|
|
| Finances |
|
|
|
| Profitability |
|
|
|
| Earnings quality |
|
|
|
| Business Predictability |
|
|
|
| PER |
- |
- |
- |
| Potential |
|
|
|
| Yield |
- |
- |
- |
| Consensus |
|
|
|
| 7 days EPS revision |
|
|
|
| 4 months EPS revision |
|
|
|
| 1 year EPS revision |
|
|
|
| 4 months Revenue revision |
|
|
|
| 1 year Revenue revision |
|
|
|
| |
|
|
|
|
Data source :
© 2013 Thomson Reuters |
|
Ratings :
© 2013 Surperformance |
|
|
|
|
|
| - Roche Holding |
6,04% |
| - Novartis |
6,04% |
| - Ventech |
5,67% |
| - Ysios Capital Partners SGECR |
5,19% |
| - LSP III Management |
4,85% |
| - ING Belgium |
4,91% |
| - Biopartners Capital SLU |
3,25% |
| - Mijnen |
3,29% |
| - Genetrix Life Sciences |
2,93% |
| - CX EBIP Agreement SLU |
2,08% |
| - LRM |
0,22% |
|
|
|
|
- Investor Relations :
Hans Herklots |
- Chief Executive Officer :
Eduardo Bravo |
- Chief Financial Officer :
Claudia D'Augusta |
|
|
| Company contact information |
|
Haasrode Researchpark 1724 Romeinse straat 12 bus 2
Po box 2
3001 Leuven
Belgium
Phone : +32 (0)16 39 60 60
Fax : +32 (0)16 39 79 70
Internet : http://www.tigenix.com
|
|
|
|
- NYSE Euronext Brussels - Compartiment C - BEL Small / |
|
|
|
|
| - ISIN Code : |
BE0003864817 |
| - Bloomberg Code : |
TIG:BB |
| - Reuters Code : |
G9U.BR |
| - Datastream Code : |
|
|
Financial data source :
© 2013 Cofisem |
|
|
